Interest of the waist-to-height ratio to predict metabolic syndrome in type 2 diabetic patients

##plugins.themes.academic_pro.article.sidebar##

Published Feb 8, 2022
Download
pdf
Vol. 100 No. 2 (2022): Issue feb 2022

##plugins.themes.academic_pro.article.main##

Imen Sebai
Ibtissem Oueslati
Meriem Yazidi
Fatma Chaker
Haifa Abdessalem
Wafa Grira
Chiraz Amrouch
Melika Chihaoui

Abstract

Introduction : Metabolic syndrome (MetS) is defined as a cluster of risk factors for cardiovascular disease.

Aim: To determine the optimal cut-off point of the waist-to-height ratio (WHtR) at which MetS can be identified with maximum sensitivity
and specificity in a sample of Tunisian type 2 diabetic patients.

Methods: We enrolled 457 type 2 diabetic patients in a cross-sectional study. Blood pressure, anthropometric indices, fasting glucose,
and lipid profile were measured. WHtR was calculated. MetS was defined according to the IDF criteria. Receiver operating characteristic
(ROC) curve analysis was used to identify the optimal cut-off value of WHtR in MetS screening with maximum sensitivity and specificity.

Results: The overall prevalence of MetS was 79.8%, it was higher in women than in men (85.5% vs 61.4%; p<10-3). Macrovascular
complications were significantly higher among patients with MetS. WHtR was more powerful for predicting MetS in men than in women
(Area under ROC curve was 0.913 and 0.761 respectively). The optimal WHtR cut-off value to identify subjects with MetS was 0.55 in
men and 0.63 in women.

Conclusion: MetS is a common finding in patients with type 2 diabetes mellitus. WHtR was an ideal tool to predict MetS in men but not
in women. Prospective studies with larger cohorts may be required to determine the validity of our results.

##plugins.themes.academic_pro.article.details##

References

  1. Karalliedde J, Gnudi L. Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease. Nephrol Dial Transplant 2016;31(2 Suppl):206-13.
  2. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res ClinPract 2018;138:271‑81.
  3. Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations, and future research. World J Diabetes 2015;6(13 Suppl):1246-58.
  4. Kalofoutis C, Piperi C, Kalofoutis A, Harris F, Phoenix D, Singh J. Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. Exp Clin Cardiol 2007;12(1 Suppl):17-28.
  5. Kaukua J, Turpeinen A, Uusitupa M, Niskanen L. Clustering of cardiovascular risk factors in type 2 diabetes mellitus: prognostic significance and tracking. Diabetes Obes Metab2001;3(1 Suppl):17-23.
  6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.Circulation 2002;106(25 Suppl):3143-421.
  7. Roberts CK, Hevener AL, Barnard RJ. Metabolic Syndrome and Insulin Resistance: Underlying Causes and Modification by Exercise Training. Compr Physiol 2013 ;3(1 Suppl):1‑58.
  8. Tenenbaum A, Fisman EZ, Motro M. Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferatoractivated receptors (PPAR). CardiovascDiabetol 2003;2:4.
  9. Obirikorang C, Obirikorang Y, Acheampong E, Anto EO, Toboh E, Asamoah EA, et al. Association of Wrist Circumference and Waist-to-Height Ratio with Cardiometabolic Risk Factors among Type II Diabetics in a Ghanaian Population. J Diabetes Res 2018; 19(1838162).
  10. Rådholm K, Chalmers J, Ohkuma T, Peters S, Poulter N, Hamet P, et al. Use of the waist-to-height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE-ON study. Diabetes ObesMetab 2018;20(8 Suppl):1903-10.
  11. World Health Organization. Obésité et surpoids. Disponible sur: http://www.who.int/fr/news-room/fact-sheets/detail/obesity-andoverweight
  12. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34(28 Suppl):2159‑219.
  13. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. EurHeart J 2016;37(39 Suppl):2999-3058.
  14. Holt RI. International Diabetes Federation re-defines the metabolic syndrome. Diabetes Obes Metab 2005;7:618-20.
  15. Youden WJ. Index for rating diagnostic tests.Cancer 1950;3(1 Suppl):32-5.
  16. Rajput R, Rajput M, Bairwa M, Singh J, Saini O, Shankar V. Waist height ratio: A universal screening tool for prediction of metabolic syndrome in urban and rural population of Haryana. Indian J Endocrinol Meta 2014;18(3 Suppl):394‑9.
  17. Osei-Yeboah J, Owiredu WKBA, Norgbe GK, Yao Lokpo S, Gyamfi J, AloteAllotey E, et al. The Prevalence of Metabolic Syndrome and Its Components among People with Type 2 Diabetes in the Ho Municipality, Ghana: A Cross-Sectional Study. Int J Chronic Dis 2017; 2017: 8765804.
  18. Ma C-M, Lu N, Wang R, Liu X-L, Lu Q, Yin F-Z. Three novel obese indicators perform better in monitoring management of metabolic syndrome in type 2 diabetes. Sci Rep 2017; 7: 9843.
  19. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24(4 Suppl):683-9.
  20. Allal-Elasmi M, Haj Taieb S, Hsairi M, Zayani Y, Omar S, Sanhaji H, et al. The metabolic syndrome: Prevalence, main characteristics and association with socio-economic status in adults living in Great Tunis. Diabetes Metab 2010;36(3 Suppl):204-8.
  21. Belfki H, Ali SB, Aounallah-Skhiri H, Traissac P, Bougatef S, Maire B, et al. Prevalence and determinants of the metabolic syndrome among Tunisian adults: results of the Transition and Health Impact in North Africa (TAHINA) project. Public Health Nutr 2013;16(4 Suppl):582‑90.
  22. Yadav D, Mishra M, Tiwari A, Bisen PS, Goswamy HM, Prasad GBKS. Prevalence of Dyslipidemia and Hypertension in Indian Type 2 Diabetic Patients with Metabolic Syndrome and its Clinical Significance. Osong Public Health Res Perspect 2014;5(3 Suppl):169‑75.
  23. Nsiah K, Shang VO, Boateng KA, Mensah F. Prevalence of metabolic syndrome in type 2 diabetes mellitus patients. Int J Appl Basic Med Res 2015;5(2 Suppl):133‑8.
  24. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med J Br Diabet Assoc 2004;21(1 Suppl):52-8.
  25. Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular Consequences of Metabolic Syndrome. TranslRes J Lab Clin Med 2017;183:57‑70.
  26. Li M, McDermott RA. Using anthropometric indices to predict cardio-metabolic risk factors in Australian indigenous populations.Diabetes Res Clin Pract 2010;87(3 Suppl):401‑6.
  27. Shen S, Lu Y, Qi H, et al. Waist-to-height ratio is an effective indicator for comprehensive cardiovascular health. Sci Rep 2017; 7: 43046.
  28. Lara-Castro C, Weinsier RL, Hunter GR, Desmond R. Visceral adipose tissue in women: longitudinal study of the effects of fat gain, time, and race. Obes Res 2002;10(9 Suppl):868-74.